CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

StatusUnknown

PhasePhase 1/2

SponsorChongqing Precision Biotech Co., Ltd

Started2023-09-07

Record status

This record was last updated August 9, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06

Trial status changed: Recruiting → Unknown

2024-08-06

Study Status, Contacts/Locations v4

Trial statusRecruiting→Unknown

2024-08-06

Study Status, Contacts/Locations v3

Study sites2→3

2023-12-06

Study Status, Arms and Interventions v2

Start dateestimated 2023-08-31→confirmed 2023-09-07

2023-08-24

Study Status, Sponsor/Collaborators, Conditions v1

Collaborators+23 characters

Shanxi Bethune Hospital

2023-08-17

Original filing

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

and 3 more diseases

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.

Trial Details

NCT Number	NCT06006390
Lead Sponsor	Chongqing Precision Biotech Co., Ltd Collaborators: Shanxi Bethune Hospital
Conditions	Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer, Lung Cancer, Breast Cancer
Enrollment	60 participants
Start Date	2023-09-07
Primary Completion	2025-12-31 (estimated)
Study Completion	2026-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-09